Heghine Khachatryan, Co-Founder and Chief Editor of Hemostasis Today, MD at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“Azacitidine plus venetoclax continues to shape the modern treatment paradigm of Acute Myeloid Leukemia (AML), particularly in patients ineligible for intensive induction chemotherapy.
Within the framework of the ASH meeting, we had the opportunity to participate in a high-level expert roundtable discussion dedicated to real-world experience with the AZA–VEN combination. The discussion focused on optimizing therapeutic sequencing, managing prolonged cytopenias, infection risk mitigation, molecular profiling, and measurable residual disease (MRD)–guided strategies.
A special honor was the opportunity to meet Professor Maria Teresa Voso and engage in dialogue with leading experts shaping the field of AML. I am also pleased to highlight that Dr. Astghik Voskanyan actively participated in this expert meeting, contributing to the discussion and representing Armenian hematology in this important international scientific exchange.
Such expert forums are essential for translating evidence into practice and strengthening global collaboration in hematologic oncology.”
Other articles featuring Heghine Khachatryan on OncoDaily.
